• note = "Funding Information: Acknowledgements The authors would like to thank all the physicians and data managers at each transplant center and the staff members of the Japanese Data Center for Hematopoietic Cell Transplantation. (elsevierpure.com)
  • Therapeutic Candidate or Device OSSM007: cryopreserved, interferon-gamma-primed bone marrow mesenchymal stem cells (BM-MSC) Indication acute Graft versus host disease (aGVHD) resulting from hematopoietic cell transplantation Therapeutic Mechanism Immunomodulation of host-reactive T cells to induce operational tolerance of donor HSC-derived lymphocytes through direct cell-to-cell contact and secreted paracrine factors. (ca.gov)
  • In select patients, high-dose chemotherapy followed by autologous hematopoietic cell transplantation may be an option at relapse. (elsevierpure.com)
  • Hematopoietic cell transplantation (HCT) is an integral part of the treatment of acute myeloid leukemia (AML). (apbmt.org)
  • Hematopoietic cell transplantation (HCT) is an effective treatment in patients with acute myeloid leukemia (AML). (apbmt.org)
  • The Japanese Society of Hematopoietic Cell Transplantation (JSHCT) has been conducting a nationwide survey on HCT since 1993, in which HCTs performed at participating centers are registered with the JSHCT every year. (apbmt.org)
  • OBJECTIVE: To assess the prognostic value of various parameters including positron emission tomography / computed tomography (PET/CT) and identify risk factors for survival of patients with non-Hodgkin's lymphoma (NHL) and Hodgkin's lymphoma (HL) treated with autologous stem cell transplantation (ASCT). (smw.ch)
  • Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. (smw.ch)
  • The place of high-dose BEAM therapy and autologous bone marrow transplantation in poor-risk Hodgkin's disease. (smw.ch)
  • Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial. (smw.ch)
  • High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma. (smw.ch)
  • High-dose sequential chemotherapy followed by autologous stem cell transplantation in relapsed and refractory aggressive non-Hodgkin's lymphoma: results of a multicenter phase II study. (smw.ch)
  • The role of intensive therapy and autologous blood and marrow transplantation for chemotherapy-sensitive relapsed and primary refractory non-Hodgkin's lymphoma: identification of major prognostic groups. (smw.ch)
  • Although children, adolescents, and young adults with newly diagnosed B-cell non-Hodgkin's lymphoma enjoy excellent overall survival with current chemoimmunotherapy, those with relapsed and/or refractory disease have a dismal prognosis. (jnccn.org)
  • Kaplan-Meier curve showing probability of overall survival in children and adolescents with mature B-cell non‐Hodgkin's lymphoma with refractory or relapsed disease during or after therapy in the FAB/LMB96 international study. (jnccn.org)
  • Earlier application of transplantation or development of additional effective antineoplastic modalities will be required to improve the results of transplantation for patients with advanced Hodgkin's disease. (umn.edu)
  • Between February 1986 and March 1990, 56 patients with relapsed Hodgkin's disease treated with high-dose cyclophosphamide, carmustine, and etoposide (CBV) received an autologous peripheral stem cell transplantation (PSCT) rather than an autologous bone marrow transplantation (ABMT) because each patient had a marrow abnormality, either hypocellularity or tumor involvement. (shengsci.com)
  • The actuarial event-free survival for these 56 patients at 3 years was 37% and was at least as good as that reported for relapsed Hodgkin's disease patients treated with CBV and ABMT. (shengsci.com)
  • CBV and PSCT for patients with relapsed Hodgkin's diseases who have marrow hypocellularity in traditional harvest sites or histopathologic evidence of BM metastases can result in long-term event-free survival. (shengsci.com)
  • Hematopoietic stem cell transplantation (HSCT) involves the intravenous infusion of hematopoietic stem cells in order to reestablish blood cell production in patients whose bone marrow or immune system is damaged or defective. (medscape.com)
  • Cells for HSCT may be obtained from the patient himself or herself (autologous transplant) or from another person, such as a sibling or unrelated donor (allogeneic transplant) or an identical twin (syngeneic transplant). (medscape.com)
  • The National Marrow Donor Program (NMDP), founded in 1986, and the World Marrow Donor Association (WMDA), founded in 1988, were established to (1) locate and secure appropriate unrelated-donor HSCT sources for patients by promoting volunteer donation of bone marrow and peripheral blood stem cells in the community and (2) promote ethical practices of sharing stem cell sources by need, rather than by geographic location of the donor. (medscape.com)
  • This, along with the development of unrelated cord blood transplantation and familial haploidentical transplantation methods, have improved the likelihood of finding an appropriate HSCT source in a timely manner. (medscape.com)
  • His research focus is on haematopoietic stem cell transplantation (HSCT) and translational research of normal and malignant stem cells. (edu.au)
  • Finally, patients with a first relapse of AML (without or with prior HSCT) clearly represent a different disease population from patients with primary chemorefractory disease or from those in second or greater relapse who collectively experience highly different outcomes. (haematologica.org)
  • In this report, we summarize the case of a patient with MM status post autologous HSCT and chronic kidney disease who experienced worsening hypertension along with a substantial increase in proteinuria shortly after the initiation of carfilzomib for the treatment of refractory disease. (biomedcentral.com)
  • The Hematopoietic stem cell transplantation (HSCT) is used in children as a definitive treatment for various oncological, immune deficiencies, hemoglobinopathy, and malignancies diseases that involve the hematological system, congenital metabolism disorders, among others. (bvsalud.org)
  • This is a quantitative, retrospective, observational, descriptive and analytical quantitative approach approaching the medical records of children and adolescents submitted to HSCT in a referral hospital service for this type of transplantation in the state of Rio Grande do Sul North (RN). (bvsalud.org)
  • Hematopoietic stem cell transplantation not responded to other therapeutic modalities, with (HSCT) is used in children as a definitive treatment an increase in survival after transplantation, for different oncological, immune deficiencies, contributing to its use (YEILIPEK, 2014). (bvsalud.org)
  • Because the chromosomal t(14;18) translocation is found in the majority of patients with follicular lymphoma, bone marrow aspiration and chromosome analysis can also help establish the diagnosis. (medscape.com)
  • Most patients with follicular lymphoma present at an advanced stage, and most patients have bone marrow involvement at diagnosis. (medscape.com)
  • To our knowledge, this is the first reported case of primary pituitary lymphoma that relapsed exclusively in the bone marrow and presented with clinical findings of idiopathic anasarca. (karger.com)
  • [ 1 ] More than half of autologous transplantations are performed for multiple myeloma and non-Hodgkin lymphoma , and the vast majority of allogeneic transplants are performed for hematologic and lymphoid cancers. (medscape.com)
  • Treatment protocols for classical Hodgkin lymphoma (HL) are provided below, including treatment for early-stage, advanced-stage, and relapsed/refractory disease. (medscape.com)
  • High dose sequential chemotherapy and autologous stem cell transplantation in patients with relapsed/refractory lymphoma. (smw.ch)
  • Overall survival of children and adolescents with mature B cell non-Hodgkin lymphoma who had refractory or relapsed disease during or after treatment with FAB/LMB 96: a report from the FAB/LMB 96 study group. (jnccn.org)
  • While still recovering from the COVID-19 pandemic crisis that greatly affected small businesses, Ilene was diagnosed with a relapse of lymphoma she treated a few years ago. (gofundme.com)
  • This multicenter, open-label phase 2 study evaluated buparlisib (BKM120), a pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or refractory non-Hodgkin lymphoma. (haematologica.org)
  • Buparlisib showed activity in relapsed or refractory non-Hodgkin lymphoma, with disease stabilization and sustained tumor burden reduction in some patients, and acceptable toxicity. (haematologica.org)
  • In the present study, the case of a patient diagnosed with diffuse large B‑cell lymphoma, who received chemotherapy and autologous hematopoietic stem cell transplantation is presented. (spandidos-publications.com)
  • The most frequent causes of secondary ITP were excluded, including lymphoma relapse, and intravenous corticosteroids were started. (spandidos-publications.com)
  • Salvage Regimens With Autologous Transplantation for Relapsed Large B-Cell Lymphoma in the Rituximab Era. (ipmj.org)
  • Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma. (ipmj.org)
  • Survival among patients with relapsed/refractory diffuse large B cell lymphoma treated with single-agent selinexor in the SADAL study. (ipmj.org)
  • Phase 1 Study of CD19 Targeted 4-1BBL Costimulatory Agonist to Enhance T Cell (Glofitamab Combination) or NK Cell Effector Function (Obinutuzumab Combination) in Relapsed/Refractory B Cell Lymphoma. (ipmj.org)
  • Waldenstrom macroglobulinemia (WM) is a B-cell lymphoplasmacytic lymphoma characterized by monoclonal immunoglobulin M protein in the serum and infiltration of bone marrow with lymphoplasmacytic cells. (elsevierpure.com)
  • The procedure is called autologous non-myeloablative haematopoietic stem-cell transplantion. (scienceblog.com)
  • Twenty-three (37%) patients remain in continuous clinical remission 1.3 to 7.7 years (median 3.8 years) after transplantation. (umn.edu)
  • They must have achieved complete remission (CR), lasting at least three months with their last induction regimen and they must have relapsed after the last regimen. (stanford.edu)
  • She underwent chemotherapy according to the L2 protocol, followed by autologous bone marrow transplantation, which produced complete remission. (unipg.it)
  • Although most clinicians would agree that hematopoietic progenitor cell transplantation after reinduction therapy is frontline therapy for these patients, there is no consensus as to what type of hematopoietic progenitor cell transplantation promises the best event-free and overall survival. (jnccn.org)
  • 1 - 3 However, those with relapsed and/or refractory (R/R) disease have had a historically dismal OS of ≤30% despite reinduction therapy and autologous hematopoietic progenitor cell transplantation (autoHCT) ( Figure 1 ). (jnccn.org)
  • Validation of prognostic factors and survival of patients with multiple myeloma in a real-life autologous stem cell transplantation setting: a Swiss single centre experience. (smw.ch)
  • While these measures have improved event-free survival (EFS) for children and adolescents/young adults with de novo AML, 30-40% of patients ultimately relapse. (haematologica.org)
  • The 30 patients who had no marrow metastases at the time of PSC harvesting had an actuarial event-free survival of 47%, while those 26 patients with marrow metastases had a significantly different actuarial event-free survival of 27% (P = .02). (shengsci.com)
  • Anti-CD45 radioimmunotherapy using (211)At with bone marrow transplantation prolongs survival in a disseminated murine leukemia model. (fredhutch.org)
  • Therapeutic Candidate or Device TriLeukeVax, an autologous AML vaccine designed to stimulate induction of anti-leukemic cytolytic activity and improve relapse free survival (RFS). (ca.gov)
  • In the last decade, the availability of autologous stem cell transplantation and combination therapies consisting of immunomodulatory drugs, proteasome inhibitors, and other chemotherapeutics has improved median 5-y survival from 34.6% in 2004 to 49.6% in 2013 ( 3 , 4 ). (snmjournals.org)
  • Our hypothesis about a splenic stem cell contributionor maintained survival compared to bone marrow transplants, to PBSCT also derives from the observation that G-CSF mobilizationsalthough graft versus host disease (GVHD) still occurs [1]. (fliphtml5.com)
  • A prospective study of lenalidomide monotherapy for relapse after Allo-SCT for multiple myeloma. (fredhutch.org)
  • A 62 year-old Caucasian man with hypertension and a 4-year history of multiple myeloma, had been previously treated with lenalidomide, bortezomib and two autologous hematopoietic stem cell transplants. (biomedcentral.com)
  • In the PETHEMA/GEM2012MENOS65 trial, 458 patients with newly diagnosed MM had longitudinal assessment of MRD after six induction cycles with bortezomib, lenalidomide, and dexamethasone (VRD), autologous transplantation, and two consolidation courses with VRD. (cun.es)
  • Options for therapy of relapsed WM besides regimens used in the front-line setting include ibrutinib, purine nucleoside analogs (cladribine, fludarabine), carfilzomib and immunomodulatory agents (thalidomide, lenalidomide). (elsevierpure.com)
  • Wu KL, van Wieringen W, Vellenga E, Zweegman S, Lokhorst HM, Sonneveld P. Analysis of the efficacy and toxicity of bortezomib for treatment of relapsed or refractory multiple myeloma in community practice. (rug.nl)
  • Low-dose filgrastim significantly enhances neutrophil recovery following autologous peripheral-blood stem-cell transplantation in patients with lymphoproliferative disorders: evidence for clinical and economic benefit. (smw.ch)
  • The landscape of relapsed pediatric AML treatment is changing rapidly, however, as the international AML community harnesses collective knowledge and resources to characterize the genetic and immunophenotypic heterogeneity of relapsed disease, identify biological targets of interest within specific AML subtypes, develop new precision medicine approaches for collaborative investigation in early-phase clinical trials, and tackle challenges of universal drug access across the globe. (haematologica.org)
  • This review provides a comprehensive overview of progress achieved to date in the treatment of pediatric patients with relapsed AML and highlights modern, state-of-the-art therapeutic approaches under active and emerging clinical investigation that have been facilitated by international collaboration among academic pediatric oncologists, laboratory scientists, regulatory agencies, pharmaceutical partners, cancer research sponsors, and patient advocates. (haematologica.org)
  • The Children's Oncology Group (COG) in North America, Ireland, New Zealand, and Australia and other cooperative groups have viewed relapse as an opportunity to test novel therapeutic agents efficiently in smaller cohorts of patients via early-phase clinical trials. (haematologica.org)
  • Giant cell tumors (GCT) of the bone are aggressive and are recognised for variable clinical behaviour, which is not always related to radiographic or histological appearance [1]. (jbstjournal.com)
  • However, melphalan efficacy is variable in the clinical population, especially in relapsed and refractory MM, and is also implicated in various toxicities, including severe mucositis and myelosuppression. (snmjournals.org)
  • National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines also recommend the use of serum free light chain assay and plasma cell fluorescence in situ hybridization (FISH) on bone marrow: del 13, del 17p13, t(4;14), t(11;14), t(14;16), t(14;20), 1q21 amplification, 1p deletion as part of the initial diagnostic workup. (medscape.com)
  • 103. Relapsed or refractory disease, as defined by the following: - Disease progression after last regimen, or - Failure to achieve a PR or CR to the last regimen 104. (who.int)
  • Given the small numbers of patients with relapsed AML and historical logistical barriers to international collaboration including poor trial funding and drug availability, the management of AML relapse has varied among pediatric oncology cooperative groups with several salvage regimens utilized and a lack of universally defined response criteria. (haematologica.org)
  • The number of related HCTs has remained stable, while the use of peripheral blood stem cells (PBSCs) has now largely replaced that of bone marrow (BM). (apbmt.org)
  • Interestingly, thiscell transplants (PBSCTs) from donors given granulocyte-colony- immature peripheral phenotype was similar to bone marrow transplantsstimulating-factor (G-CSF) has decreased relapse rates and improved before G-CSF. (fliphtml5.com)
  • For induce splenomegaly in most donors and in rare, severe cases splenicautologous stem cell transplants, the use of autologous PBSCT from rupture [13,14]. (fliphtml5.com)
  • There are multiple mechanisms and differential diagnosis includes: artifactual thrombocytopenia, accelerated platelet destruction (intra- or extra-corpuscular anomalies), deficient production (bone marrow failure, disordered proliferation or thrombopoietin deficiency), and abnormal distribution (disorders associated with splenomegaly or dilution in massive transfusions) ( 1 ). (spandidos-publications.com)
  • Relapse of neuroblastoma commonly occurs in hypoxic tissues, and is associated with an acquired and sustained high-level drug resistance, often due to p53 loss of function. (aacrjournals.org)
  • 8 Despite high response rates to rituximab-based regimens, many patients become resistant to treatment or relapse after initially achieving a response. (haematologica.org)
  • A liver biopsy and paracentesis were transplant (SCT), she experienced a relapse of disease performed on day 85. (cdc.gov)
  • In cases of unrelated HCT, PBSC transplantation (PBSCT) still comprises only a very small percentage, which reflects the fact that unrelated PBSCT did not come into use in Japan until 2010. (apbmt.org)
  • Transduction of CLL cells by CD40 ligand enhances an antigen-specific immune recognition by autologous T cells. (shengsci.com)
  • We focus on destroying only the immune component of the bone marrow and then regenerate the immune component, which makes the procedure much safer and less toxic than traditional chemotherapy for cancer," Burt said. (scienceblog.com)
  • Zhang QY, Foucar K. Bone marrow involvement by Hodgkin and non-Hodgkin lymphomas. (medscape.com)
  • 1 , 2 , 4 - 6 Specifically, patients with lactate dehydrogenase ≥2 times the upper limit of normal (ULN) at diagnosis, R/R disease within 6 months of diagnosis, multisite relapse, and/or R/R disease with bone marrow involvement experience a significantly decreased OS ( Table 1 ). (jnccn.org)
  • No involvement of the bone marrow and peripheral blood was found. (unipg.it)
  • Furthermore, in hematologic malignancies, low degrees of circulating IL-15 after bone tissue marrow transplantation had been predictive of threat of relapse (49). (eotp.org)
  • Therapeutic Candidate or Device The therapeutic candidate is a patient specific (autologous) induced pluripotent stem cell derived retinal pigment epithelium (AiPSC-RPE) product. (ca.gov)
  • Since its establishment in 2010, the Adult AML Working Group within the JSHCT has been using this registry data to complete several studies focusing on various aspects of HCT in adults with AML, with particular attention paid to patient-, disease-, and transplantation-related factors. (apbmt.org)
  • 5% blasts in the bone marrow not attributable to another cause. (stanford.edu)
  • Accordingly, this boost of receptor appearance was correlated with a rise of organic cytotoxicity against autologous AML blasts (29, 48). (eotp.org)
  • In this process, the donor lays on their stomach so the physician can insert a needle into the iliac crest, located at the back of the pelvic bone. (discovermagazine.com)
  • eg, bone, bone marrow, and skin grafts) Genetically identical (syngeneic [between monozygotic twins]) donor tissue (isografts) Genetically. (msdmanuals.com)
  • Various factors including age, sex, performance status (PS), disease status, cytogenetic risk, donor type, graft source, sex mismatch between the donor and the recipient, and year of transplantation were all shown to impact OS 2 . (apbmt.org)
  • Within 10 to 15 years after onset of the disease, most patients with this relapsing-remitting MS progress to a later stage called secondary progressive multiple sclerosis. (scienceblog.com)
  • The 21 patients in the trial, ages 20 to 53, had relapsing-remitting multiple sclerosis that had not responded to at least six months of treatment with interferon beta. (scienceblog.com)
  • During this time, she is undergoing a costly treatment, which includes chemotherapy and autologous bone marrow transplantation. (gofundme.com)
  • However, access to new drugs of biological interest in pediatric AML is not equal among countries and continents, which has further affected the ability to investigate promising approaches and to standardize treatment more globally in the relapsed setting. (haematologica.org)
  • The goal of treatment of this tumor at the distal radius is complete removal of the tumor and reconstruction of the bone defect in order to preserve maximum function of the wrist joint. (jbstjournal.com)
  • In July 2012, a new member in its class, carfilzomib, was approved by the FDA for the treatment of relapsing or refractory MM. (biomedcentral.com)
  • In symptomatic patients relapsing more than 1-2 years after initial therapy, the original treatment can be repeated. (elsevierpure.com)
  • MM is considered relative paucity of CNS invasion by MM an incurable disease despite various meth- in comparison with other tumours, whether ods of treatment, including autologous bone solid or haematological, remain unknown, marrow transplantation [ 3 ]. (who.int)
  • Myeloma cells produce excess abnormal proteins, called paraproteins, in the bone marrow that can cause your blood to become so thick that it flows sluggishly in your body, a condition called hyperviscosity. (webmd.com)
  • The findingssupport the hypothesis that G-CSF mobilizes two distinct stem cell populations, one from the bone marrow andthe other from the spleen. (fliphtml5.com)
  • Ibrutinib is taken to decrease the size of lymph nodes, decrease the size of an enlarged liver or spleen, or to increase the number of good cells made in the bone marrow. (chemoexperts.com)
  • HCT, whether it be autologous, allogeneic, or tandem, has been and continues to be an integral part of therapy, with varying outcomes as delineated in Table 2 . (jnccn.org)
  • Temporal bone chemodectomas--comparing surgery and radiation therapy. (uchicago.edu)
  • A new agent in this class, carfilzomib, has been recently introduced as alternative therapy for relapsing and refractory multiple myeloma. (biomedcentral.com)
  • Relapse is almost inevitable in WM but may occur years after initial therapy. (elsevierpure.com)
  • Subsequently, his serum creatinine stabilized at 2.1 mg/dL (185.64 μmol/L). Seventeen months after the second hematopoietic stem cell transplant, he was initiated on carfilzomib for relapse of multiple myeloma. (biomedcentral.com)
  • The Berlin-Frankfurt-Münster (BFM) group in Europe has historically used relapsed disease as an opportunity to conduct large randomized trials. (haematologica.org)
  • This work was supported in part by the Practical Research Project for Allergic Diseases and Immunology (Research Technology of Medical Transplantation) from the Japan Agency for Medical Research and Development, AMED, under Grant Number 19ek0510023h0002. (elsevierpure.com)
  • Worldwide, approximately 90,000 first HSCTs-53% autologous and 47% allogeneic-are performed every year, according to the World Wide Network of Blood and Marrow Transplantation. (medscape.com)
  • Professor Ma holds leadership or scientific membership positions in a number of national and international scientific communities including the World Network for Blood & Marrow Transplantation (a WHO affiliated NGO), the AsiaPacific BM Transplant and the Royal College of Pathology of Australasian Quality Assurance Programme. (edu.au)
  • Multiple myeloma (MM) is a cancer of terminally differentiated plasma B cells that originates in the hematopoietic bone marrow and accounts for 15%-20% of all hematologic malignancies ( 1 , 2 ). (snmjournals.org)
  • Therapeutic Candidate or Device Hematopoietic stem and progenitor cells collected from X-CGD patients modified with a highly regulated lentiviral vector Indication X-linked Chronic Granulomatous Disease Therapeutic Mechanism Lentiviral vector (LV) modification of autologous hematopoietic stem and progenitor cells (HSPCs) to restore physiologic gp91phox expression. (ca.gov)